{"entity":{"id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","aka":[],"tldr":"A phase 1/2 trial of MCLA-129 in triple-negative breast cancer, run by Shenzhen Majory Biotechnology Co., Ltd., now recruiting.","summary":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) is a phase 1/2 interventional study registered as NCT07208149 by Shenzhen Majory Biotechnology Co., Ltd., with 42 participants planned, started 2026-01-29 and due to reach its primary completion in 2028-09-01. Interventions recorded: MR001 Bispecific Antibody for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07208149","url":"https://clinicaltrials.gov/study/NCT07208149"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":["mcla-129"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07208149","phase":"1/2","setting":"A Phase Ib/IIa, Open-Label, Two-Cohort, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) Who Have Progressed After First-Line or Later-Line Therapy","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","participation":[{"nct":"NCT07208149","source":"https://clinicaltrials.gov/study/NCT07208149","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"ec0c54a5df89bf304c532ce2c2a06bb98c250583c6aaf88072db0805a6ea0c6e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-02-12","leadSponsor":"Shenzhen Majory Biotechnology Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":42,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-01-29","startedType":"actual","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07208149/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/"}]}}